Asfar Azmi

Asfar Azmi

Asfar Azmi

Position Title

Associate Professor
Basic Science

Office Location

Karmanos Cancer Institute
Hudson-Webber Cancer Research Center - 740.1
4100 John R.
Detroit, MI 48201

Mailing Address

Karmanos Cancer Institute
4100 John R., HW07AO
Detroit, MI 48201

Office Phone

313-576-8328

Education Training

Education
(2006) Ph.D. Biochemistry, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
(2002) M.S. Biochemistry, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
(2000) B.S. with honors Biochemisty, Aligarh Muslim University, Aligarh, Uttar Pradesh, India

Postgraduate Training
(2011-2014) Research Scientist, Department of Pathology, Wayne State University School of Medicine, Detroit, MI
(2009-2011) Research Associate, Department of Pathology, Wayne State University School of Medicine, Detroit, MI
(2007-2009) Postdoctoral Research Fellow, Department of Pathology, Wayne State University School of Medicine, Detroit, MI

Professional Experience

Faculty Appointments

(2020 - Present) Associate Professor, Department of Oncology, Wayne State University School of Medicine.
(2016 - 2020) Tenure Track Assistant Professor, Department of Oncology, Wayne State University School of Medicine
(2016 - Present) Cancer Biology Graduate Faculty, Wayne State University School of Medicine
(2015 - Present) Scientific Member, Molecular Therapeutics Program, Karmanos Cancer Institute
(2014 - 2016) Assistant Professor, Department of Oncology, Wayne State University School of Medicine

 

Major Professional Societies

American Association for Cancer Research
American Pancreatic Association

Honors and Awards

(2018) NIH R37 MERIT AWARD [R01 was converted into a 7 year MERIT award by the NCI in view of the outstanding score]
(2018) Wayne State University School of Medicine Research Excellence Award
(2018) Wayne State Academy of Scholars, Young Investigator Award Associate Editor BMC Cancer
(2015) American Association for Cancer Research (AACR) Young Investigator Award
(2014) American Association for Cancer Research (AACR) Young Investigator Award
(2012) American Pancreatic Association (APA) Young Investigator Award 2012
(2012) American Society of Hematology (ASH) Abstract Achievement Award 2012
(2011) President Postdoctoral Association, Wayne State University
(2010) Vice President Postdoctoral Association, Wayne State University
(2007) Elsevier Highest Cited Author Award from Seminars in Cancer Biology
(2005-2006) Govt of India, Senior Research Fellowship Award Council of Scientific and Industrial Research

Courses taught

CB 7460: Mechanisms of Neoplasia - Alterations to Cellular Signaling
 

Publications

Peer reviewed
Reports of original work (*trainee)

1. Khan HY*, Ge J*, Nagasaka M, Aboukameel A*, Mpilla G*, Muqbil I, Szlaczky M, Chaker M*, Baloglu M, Landesman Y, Mohammad RM, Azmi AS, Sukari A. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int. J. Mol. Sci. 2020, 21, 237; doi:10.3390/ijms21010237. PMID in process
2. Azmi AS, Khan HY*, Muqbil I, Aboukameel A*, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M*, Al Hallak MN*, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. PMID: 31831564
3. Mpilla G*, Aboukameel A*, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M*, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors Cancers 2019, 11(12), 1902
4. Sexton R*, Mahdi Z*, Chaudhury R*, Beydoun R, Aboukameel A*, Khan HY*, Baloglu E, Senapedis W, Landesman Y, Tesfaye A*, Kim S, Philip PA, Azmi AS. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. Int J Mol Sci. 2019 Sep 28;20(19). pii: E4826. doi:
10.3390/ijms20194826. PMID:31569391 5. Muqbil I, Chaker M*, Aboukameel A*, Mohammad RM, Azmi AS and Ramchandren. Pre-clinical antitumor activity of Bruton’s Tyrosine Kinase Inhibitor in Hodgkin’s Lymphoma Cellular and Subcutaneous Tumor Model. Heliyon (Accepted article in Press)
6. Azmi AS, Li Y*, Aboukameel A*, Muqbil I, Philip PA, Mohammad RM. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101. PMID: 31382411
7. Aboukameel A*, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI and Azmi AS. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget. 2018; 9:35327-35342. (Role: Corresponding author). Impact factor 5.135.  Number of times cited: 1. [The importance of this article was highlighted by an accompanying independent commentary article and published by a senior expert Emmanuel S. Antonarakis in Oncotarget. 2018 Nov 9;9(88):35797-35798. doi: 10.18632/oncotarget.26296.]
8. Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B Biointerfaces. 2018 Jul 1;167:8-19. doi: 10.1016/j.colsurfb.2018.03.046. Epub 2018 Mar 28. (Role: data analysis writing and editing). Impact factor 4.152. Number of times cited 10.
9. Azmi AS, Li Y*, Muqbil I, Aboukameel A*, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA and Mohammad RM. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget 2017 Jul 17;8(47):82144-82155. (role: Data collection, data analysis, writing manuscript). Impact factor 5.135. Number of times cited 12.
10. Mohammad RM, Li Y*, Muqbil I, Aboukameel A*, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-BadmicroRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases. 2017 Jun 22:0. doi: 10.1080/21541248.2017.1329694. [Epub ahead of print]. PMID: 28641032 (Role: corresponding author). Impact factor 1.8. Number of times cited: 8.
11. Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869. PMID: 28574828 (Role: data analysis, writing). Impact factor 5.135. Number of times cited: 7.
12. Aboukameel A*, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM and Azmi AS. Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2017 Jan;16(1):76-87. (Role: Corresponding author). Impact factor 5.135. Number of times cited: 23. [The findings from this article drove a Phase I clinical study entitled “PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)” ClinicalTrial.gov identifier NCT02702492]
13. Muqbil I, Aboukameel A*, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D*, Zonder J, Azmi AS, Mohammad RM. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Lett. 2016 28;383(2):309-317. PMID: 27693556 (Role: Data acquisition, analysis, data interpretation). Impact factor 6.375. Number of times cited: 13.
14. Kashyap T, Argueta C, Aboukameel A*, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016 Oct 4. doi: 10.18632/oncotarget.12428. PMID:27713151 (Role: data acquisition, writing and editing the manuscript). Impact factor 5.135. Number of times cited: 23
15. Azmi AS, Muqbil I, Wu J, Aboukameel A*, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077. (Role: corresponding author). Impact factor: 4.122. Number of times cited: 17
16. Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Aboukameel A*, Mohammad R, Van Buren E, Azmi AS, Sarkar FH. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev. 2014 Aug 15;23(16):1947-58. doi: 10.1089/scd.2013.0551. Epub 2014 Jun 6. PubMed PMID: 24734907. Impact factor 3.315. Number of times cited 26.
17. Bao B, Azmi AS, Aboukameel A*, Ahmad A, Bollig-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem. 2014 23;289(21):14520-33. PubMed PMID: 24719318. (Role: experimental design, writing and editing manuscript). Impact factor 4.125. Number of times cited 42.
18. Abdulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A*, Maddy AS, Gullapa AS, Stuckey JA, Mohammad RM, Nikolvska-Coleska Z. Mcl-1 inhibitor for pancreatic cancer therapy. Molecular Cancer Therapeutics. 2014 Mar;13(3):565-75. doi: 10.1158/1535-7163.MCT-12-0767 (Role: data collection, writing and editing manuscript). Impact factor 5.135. Number of times cited 104.
19. Gao J, Azmi AS, Kauffman M, Abousamra AB, Shacham S, Mohammad RM. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget 2014 Jun 15;5(11):3444-54. (Role: data collection, writing and editing manuscript).
Impact factor 5.168. Number of times cited 31.
20. Azmi AS, Bollig-Fischer A, Bao B, Park BJ, Lee SH, Yong-Song G, Dyson G, Reddy CK, Sarkar FH, Mohammad RM. Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. BMC Syst Biol. 2013 3;7:85. PubMed PMID: 24004452. (Role: co-corresponding author). Impact factor 2.05. Number of times cited 17.
21. Azmi AS, Al-Katib A, Aboukameel A*, McCauley D, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's Lymphomas. Haematologica. 2013 98(7):1098-106. Impact factor 5.817. Number of times cited 47. [The findings of this article led to the initiation of a Phase Ib/II clinical study entitled “Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma” ClinicalTrial.gov identifier NCT03147885]
22. Azmi AS, Aboukameel A*, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology. 2013 144(2):447-56. PubMed PMID: 23089203. (Role: Data collection, writing and editing). Impact factor. 18.187. Number of times cited 88. [This article featured on the cover of Gastroenterology Journal that has an impact factor of >18. This article was accompanied with an American Gastroenterology Association Blog entitled “Can We Increase the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutics?” written by the Academic Editor Kristine Novak. The studies of this article led to a Phase Ib/II clinical study entitled “Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer” ClinicalTrial.gov identifier NCT02178436. This article has been highlighted on several occasions by the Karmanos Cancer Institute at External Advisory Board (EAB) meetings. This article was included in the Karmanos Cancer Institute CCSG grant renewal document and was the data was presented during the core center grant renewal process and
NCI site visit]
23. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee S, Padhye S, Sarkar FH. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 2012;7(8):e43726. PubMed PMID: 22952749. (Role: writing and editing). Impact factor 2.806. Number of times cited 102.
24. Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A*, Padhye SB, Sarkar FH. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One. 2012;7(12):e50165. PubMed PMID: 23272057. (Role: experimental design, writing and editing). Impact factor 2.806. Number of times cited 116
25. Alian OM*, Azmi AS Mohammad RM. Network Insights on Oxaliplatin Anti-Cancer Mechanisms. Clin Transl Med. 2012 Oct 29;1(1):26 (Role: writing and editing). RG Journal impact factor: 4.08. Number of times cited: 17
26. Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y. Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS One. 2012;7(12):e52095. (Role: data interpretation, writing and editing). Impact factor. 2.806. Number of times cited: 43.
27. Shamim U, Hanif S, Albanyan A, Beck FW, Bao B, Wang Z, Banerjee S, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol. 2012; 227(4):1493-500. PubMed PMID: 21678400. Impact factor 4.080. Number of times cited 43.
28. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012 Mar;5(3):355-64. PubMed PMID: 22086681. (Role: experimental design writing and editing). Impact factor 4.021. Number of times cited 303.
29. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012 1;72(1):335-45. PubMed PMID: 22108826. (Role: experimental design, writing and editing manuscript). Impact factor 10.199. Number of times cited 251
30. Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011 15;3(4):374-82. PubMed PMID: 21904657. (Role: Data collection, writing and editing manuscript). Impact factor 2.829. Number of times cited 21.
31. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011; 2(5):378-92. PubMed PMID: 21623005. (Role data collection, writing and editing manuscript). Impact factor 5.168. Number of times cited 44
32. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 6;30(1):117-26. doi: 10.1038/onc.2010.403. PubMed PMID: 20818437. (Role: data collection, writing and editing manuscript). Impact factor 6.854. Number of times cited 45.
33. Hadi SM, Ullah MF, Shamim U, Bhatt SH, Azmi AS. Catalytic Therapy of Cancer by Ascorbic Acid Involves Redox Cycling of Exogenous/Endogenous Copper Ions and Generation of Reactive Oxygen Species. Chemotherapy. 2010;56(4):280-284. Epub 2010 Aug 11. PMID: 20714144. (Role: text editing). Impact factor 1.45. Number of times cited: 27.
34. Mohammad RM, Wu J, Azmi AS, Aboukameel A*, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2010; 8:115 (Role: data interpretation and text editing). Impact factor 7.76. Number of times cited: 80.
35. Azmi AS, Philip PA, Aboukameel A*, Wang Z, Banerjee S, Zafar SF*, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010 May;10(3):319-31. PubMed PMID: 20370686. (Role: data collection, writing and editing manuscript). Impact factor 2.62. Number of times cited 49.
36. Azmi AS, Aboukameel A*, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer. 2010 Apr;46(6):1122-31. PubMed PMID: 20156675. Impact factor 7.19. Number of times cited: 52
37. Ullah MF, Shamim U, Hanif S, Azmi AS, Hadi SM. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Mol Nutr Food Res. 2009 Nov;53(11):137 (Data collection, data interpretation, manuscript writing and editing). Impact factor: 5.15.
Number of times cited: 45.
38. Nazeem S, Azmi AS, Hanif S, Ahmad A, Mohammad RM, Hadi SM, Kumar KS. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis. 2009 Sep;24(5):413-8 (Role: Data collection, data interpretation, manuscript writing and editing). Impact factor 2.84. Number of times cited: 47
39. Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A*, Mohammad RM. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol. 2009 Feb 16;2:8. (Role: study design, data collection and text editing). Impact factor 7.33. Number of times cited: 29
40. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM. TW-37, a smallmolecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 2009 Apr 1;69(7):2757-65. doi:
10.1158/0008-5472.CAN-08-3060. Epub 2009 Mar 24. PMID: 19318573. Impact factor 10.19. Number of times cited 78.
41. Shamim U, Hanif S, Ullah MF, Azmi AS, Bhat SH and Hadi SM. Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: implications for anticancer mechanism. Free Radical Research (2008) 25, 1-9. (Role: Manuscript editing, experimental design). Impact factor 3.03. Number of times cited: 51
42. Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther. 2008 Sep;7(9):2884-93. PubMed PMID: 18790769. (Role: Data collection, writing and editing manuscript). Impact factor 5.365. Number of times
cited 37.
43. Sarmad Hanif, Shamim U, Ullah F, Azmi AS, Bhat SH and Hadi SM. The Anthocyanidin delphinidin mobilizes endogenous copper ions from human peripheral lymphocytes leading to oxidative degradation of cellular DNA. Toxicology. (2008). 10: 249(1), 19-25. (Role: Study design, manuscript writing and editing). Impact factor 3.639. Number of times cited: 37.
44. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res. 2008 Sep;25(9):2117-24. PubMed PMID: 18427961. Impact factor. 3.335. Numbero of times cited 57.
45. Nazeem S, Azmi AS, Sarmad Hanif, Satheesh K. Reactive oxygen dependent DNA damage resulting from the oxidation of plumbagin by a copper-redox cycle mechanism: Implications for anticancer properties. Austral-Asian Journal of Cancer (2008): 7 (1) 41-48. (Role: Data collection, data interpretation, manuscript writing and editing). Impact factor: none available.
46. Bhat Hussain, Azmi AS, Hadi S.M. Prooxidant DNA breakage induced by caffeic acid in human peripheral lymphocytes: Involvement of endogenous copper and a putative mechanism for anticancer properties. Toxicol Appl Pharmacol. (2007) 218(3):249-55. (Role: Data collection, data interpretation, manuscript writing and editing). Impact factor 3.616. Number of times cited: 80.
47. Azmi AS, Bhat Showket, Hanif Sarmad, Hadi S.M. Plant polyphenols mobilize endogenous Copper ions in human peripheral lymphocytes leading to oxidative DNA breakage: A putative mechanism for anticancer properties. FEBS Letters. (2006) 580 (2):533-38. Impact factor 3.519. Number of times cited: 167.
48. Bhat Showket, Azmi AS, Hanif Sarmad, Hadi S.M. Ascorbic acid mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for anticancer properties. Int J Biochem Cell Biol. (2006) 38 (12):2074-81. (Role: Data collection, data interpretation, manuscript writing and editing). Impact factor 3.247. Number of times cited 37.
49. Muqbil Irfana, Azmi AS, Banu Naheed. Prior exposure to restraint stress enhances 7; 12-dimethylbenz anthracene (DMBA) induced DNA damage in rats. FEBS Letters. (2006) 580 (16):3995-99. (Data collection, data interpretation, manuscript writing and editing). Impact factor 3.519, Number of times cited: 35
50. Azmi AS, Bhat SH, Hadi S.M. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: Implications for anticancer properties. FEBS Letters (2005) 579 (14):3131-35. Impact factor 3.519. Number of times cited: 129.
51. Uddin Q, Malik A, Azam S, Hadi N, Azmi AS, Perveen N, Khan N.U, Hadi S.M. The Biflavonoid amentoflavone degrades DNA in the presence of copper ions. Toxicology In vitro. (2004) 18:435-40. (Data collection, data interpretation, manuscript writing and editing).Impact factor 3.1. Number of times cited: 13.


Review articles (peer reviewed)
1. Sexton RE*, Mpilla G*, Kim S, Philip PA, Azmi AS. Ras and exosome signaling. Semin Cancer Biol. 2019 Feb;54:131-137. doi: 10.1016/j.semcancer.2019.02.004. Epub 2019 PMID: 30769101 (Corresponding author)
2. Tesfaye AA*, Azmi AS, Philip PA. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. Am J Pathol. 2019 Jan;189(1):58-70. doi: 10.1016/j.ajpath.2018.10.005. PMID: 30558723 (Writing and editing)
3. Muqbil I, Azmi AS, Mohammad RM. Nuclear Export Inhibition for Pancreatic Cancer Therapy. Cancers (Basel). 2018 May 7;10(5). pii: E138. doi: 10.3390/cancers10050138. Review. PMID: 29735942
4. Tesfaye AA*, Kamgar M*, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148 (writing and editing)
5. Chaker M*, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets. 2018 Jan;22(1):9-17. (corresponding author)
6. Diab M*, Muqbil I, Mohammad RM, Azmi AS, Philip PA. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med. 2016 Jun 16;5(6). pii: E59. doi: 10.3390/jcm5060059. Review. PMID: 2732233 (Role: wrote and edited manuscript).
7. Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016 Jan 21. pii: S1044-579X(16)30002-5. doi: 10.1016/j.semcancer.2016.01.002. PMID: 26804424
8. Amin AR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, Shin DM. Evasion of antigrowth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol. 2015 Dec;35 Suppl:S55-77. doi:
10.1016/j.semcancer.2015.02.005 (Role: writing and editing)
9. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015 Dec;35 Suppl:S185-98. doi:
10.1016/j.semcancer.2015.03.004 (Role: writing and editing)
10. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D. Semin Cancer Biol. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. 2015 Dec;35 Suppl:S244-75. doi: 10.1016/j.semcancer.2015.03.008 (Role: writing and editing).
11. Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, Helferich WG, Heneberg P, Honoki K, Keith WN, Kerkar SP, Mohammed SI, Niccolai E, Nowsheen S, Vasantha Rupasinghe HP, Samadi A, Singh N, Talib WH, Venkateswaran V, Whelan RL, Yang X, Felsher DW. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015 Dec;35 Suppl:S199-223. doi: 10.1016/j.semcancer.2015.02.007 (Role: writing and editing).
12. Yaswen P, MacKenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J, Firestone GL, Matheu A, Carnero A, Bilsland A, Sundin T, Honoki K, Fujii H, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Niccolai E, Aquilano K, Ashraf SS, Nowsheen S, Yang X. Therapeutic targeting of replicative immortality. Semin Cancer Biol. 2015 Dec;35 Suppl:S104-28. doi: 10.1016/j.semcancer.2015.03.007 (Role: writing and editing).
13. Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR, Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed SI, Niccolai E, Yang X, Honoki K, Parslow VR, Prakash S, Rezazadeh S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24. doi: 10.1016/j.semcancer.2015.03.005 (Role: writing and editing).
14. Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54. doi:
10.1016/j.semcancer.2015.02.006 (Role: writing and editing).
15. Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103. doi: 10.1016/j.semcancer.2015.03.001.
16. Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis C, Boosani CS, Poudyal D, Stafforini DM, Bhakta D, Niccolai E, Guha G, Vasantha Rupasinghe HP, Fujii H, Honoki K, Mehta K, Aquilano K, Lowe L, Hofseth LJ, Ricciardiello L, Ciriolo MR, Singh N, Whelan RL, Chaturvedi R, Ashraf SS, Shantha Kumara HM, Nowsheen S, Mohammed SI, Keith WN, Helferich WG, Yang X. A multi-targeted approach to suppress tumorpromoting inflammation. Semin Cancer Biol. 2015 Dec;35 Suppl:S151-84. doi:
10.1016/j.semcancer.2015.03.006 (Role: writing and editing)
17. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Helifax consortium. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015 Dec;35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007 (Role: writing and editing).
18. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith N, Jensen LD. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015 Jan 16. pii: S1044-579X(15)00002-4. doi: 10.1016/j.semcancer.2015.01.001. Review. PMID: 25600295 (Role: reference library editing, language editing).
19. Muqbil I, Wu J, Aboukameel A*, Mohammad RM, Azmi AS. Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition. Seminars in Cancer Biology. 2014 Aug;27C:39-45. 20. Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med. 2014 Jun;2(6):59. PubMed PMID: 25333034.
21. Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. Future Med Chem. 2014 Apr;6(5):529-39. doi: 10.4155/fmc.14.6.
22. Al-Hajeili M*, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther. 2014 Feb 4;7:187-192. eCollection 2014. Review. (Role: writing and editing)
23. Alian OM*, Philip PA, Sarkar FH, Azmi AS. Systems biology approaches to pancreatic cancer detection, prevention and treatment. Curr Pharm Des. 2014;20(1):73-80. PubMed PMID: 23530496.
24. Muqbil I, Kauffman M, Shacham S, Mohammad RM and Azmi AS. Understanding CRM1 Target Networks Using Systems Biology and Mathematical Modeling. Current Pharmaceutical Design. 2014;20(1):56-65.
25. Bao B, Azmi AS, Li Y, Ahmad A, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther. 2014 Jan;9(1):22-35. PubMed PMID: 23957937.
26. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013 Dec;32(3-4):623-42. PubMed PMID: 23709120.
27. Azmi AS. Unveiling the role of nuclear transport in EMT. Current Cancer Drug Targets. 2013. Nov;13(9):906-14 (Role: writing and editing).
28. Muqbil I, Kauffman M, Shacham S, Mohammad RM and Azmi AS. Nuclear Export Regulation of miRNAs in Cancer: Opportunities for Therapeutic Intervention. Current Drug Targets 2013. Sep;14(10):1094-100.
29. Azmi AS, Bao GW, Gao J, Mohammad RM, Sarkar FH. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review. Curr Drug Discov Technol. 2013 Jun;10(2):147-54. Review. PubMed PMID: 23237677; PubMed Central PMCID: PMC3820112.
30. Azmi AS, Sarkar FH, Hadi SM. Pro-oxidant activity of dietary chemopreventive agents: an underappreciated anti-cancer property. F1000Res. 2013 Jun 4;2:135. doi: 10.12688/f1000research.2-135.v1. eCollection 2013. PubMed PMID: 24358870
31. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013 Jun;Chapter 14:Unit 14.25. PubMed PMID: 23744710.
32. Muqbil I, Bao GW, El-Kharraj R, Shah M, Mohammad RM, Sarkar FH, Azmi AS. Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. J Stem Cell Res Ther. 2012 Dec 16;Suppl 7(5). pii: 10413. PubMed PMID: 24319631.
33. Azmi AS. Adopting Network Pharmacology for Cancer Drug Discovery. Curr Drug Discov Technol. 2012 Dec 10. 2013 Jun;10(2):95-105. PMID: 23237672
34. Bao B, Li Y, Ahmad A, Azmi AS, Bao G, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSCrelated miRNAs for cancer therapy by natural agents. Curr Drug Targets. 2012 Dec;13(14):1858-68. Review. PubMed PMID: 23140295; PubMed Central PMCID: PMC3792656.
35. Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets. 2012 Oct;16(10):1041-54. Review. PubMed PMID: 22877147.
36. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. 2012 Dec;1826(2):272-96. PubMed PMID: 22579961.
37. Muqbil I, Beck FW, Bao B, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Curr Pharm Des. 2012;18(12):1645-54. Review. PubMed PMID: 22288443.
38. Bao B, Thakur A, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Ali S, Lum LG, Sarkar FH. The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. Biochim Biophys Acta. 2012;1825(2):160-72. PubMed PMID: 22155217.
39. Nishat S, Shabir H, Azmi AS, Ansari HR. A3 Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes. Recent Pat Cardiovasc Drug Discov. 2012 Apr 1;7(1):59-70. (Role: text editing).
40. Azmi AS, Beck FW, Bao B, Mohammad RM, Sarkar FH. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics. 2011;3(6):747-59. PubMed PMID: 22126293.
41. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 2011 Apr;31(4):1105-13. Review. PubMed PMID: 21508353.
42. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2011 Mar;16(1):59-70. Review. PubMed PMID: 20812891.
43. Azmi AS, Beck FW, Sarkar FH, Mohammad RM. Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr Pharm Des. 2011;17(6):640-52. Review. PubMed PMID: 21391913.
44. Masood A*, Azmi AS and Ramzi M. Mohammad. Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic cancer Therapy. Cancers 2011, 3, 1527-1549. (Role: text editing)
45. Muqbil I, Masood A*, Sarkar FH, Mohammad RM, Azmi AS. Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. Cancers (Basel). 2011 Jan 21;3(1):428- 45. doi: 10.3390/cancers3010428. PubMed PMID: 24212623.
46. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Sarkar FH. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):27-33. PubMed PMID: 21102532.
47. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther. 2010 Dec;9(12):3137-44. Review. PubMed PMID: 21041384.
48. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):258-67. doi: 10.1016/j.bbcan.2010.06.001. Review. PubMed PMID: 20600632.
49. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta. 2010 Aug;1806(1):122-30. doi: 10.1016/j.bbcan.2010.04.003. Epub 2010 Apr 28. Review. PubMed PMID: 20434526.
50. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat. 2010 Aug-Oct;13(4-5):109-18. PubMed PMID: 20692200.
51. Hadi SM, Ullah MF, Azmi AS, Ahmad A, Shamim U, Zubair H, Khan HY. Resveratrol Mobilizes Endogenous Copper in Human Peripheral Lymphocytes Leading to Oxidative DNA Breakage: A Putative Mechanism for Chemoprevention of Cancer. Pharm Res. 2010 Jun; 27(6):979-88. (Role: writing editing).
52. Azmi AS, Philip PA, Zafar SF*, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets. 2010;14(6):611-20. PubMed PMID: 20426700. (Role: writing editing).
53. Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 Jun;10(6):518-26. Review. PubMed PMID: 20377522. (Role: writing editing).
54. Azmi AS and Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. Journal of Cellular Physiology. J Cell Physiol. 2009 218(1):13-21. (Role: writing editing).
55. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008 Apr;34(2):122-36. Review. PubMed PMID: 18162327.
56. Hadi SM, Bhat SH, Azmi AS, Hanif S, Shamim U, Ullah F. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol. (2007) 17(5):370-6. (Role: writing and editing)


Editorial Commentaries
1. Azmi AS, Cagir A. Novel KRASG12C Inhibitors on the horizon: Future Medicinal Chemistry. 2019. In press. DOI: 10.4155/fmc-2018-0304
2. Azmi AS. Some chinks in Ras armor. Seminars in Cancer Biology. 2018 54:iii-iv. doi: 10.1016/j.semcancer.2018.08.005. PMID: 30092255
3. Azmi AS. Nuclear export mechanisms of circular RNAs: size does matter. Noncoding RNA Investig. 2018 Sep;2. pii: 52. doi: 10.21037/ncri.2018.08.03. PMID: 30393780
4. Azmi AS, Mohammad RM. Targeting Cancer at the Nuclear Pore. J Clin Oncol. 2016 Dec;34(34):4180-4182. PMID: 27863200
5. Azmi AS. Opening a pandora’s (F)-Box in cancer. Semin Cancer Biol. 2016 Feb;36:1-2. doi: 10.1016/j.semcancer.2015.12.001. PMID: 26706999
6. Azmi AS, Mohammad RM, P21 activated kinase 4 (PAK4): a therapeutic target in the elusive Kras pathway. Future Medicinal Chemistry. 2015 (1):5-7. doi: 10.4155/fmc.14.144. PMID: 25582328.
7. Azmi AS. The evolving role of the nuclear transporters in cancer. Seminars in Cancer Biology. 2014 Aug;27:1-2. PMID: 24793699.
8. Azmi AS. Network Pharmacology: an emerging area in anti-cancer drug discovery Current Drug Discovery Technology. 2013 Jun;10(2):93-4. PMID: 23237671.
9. Azmi AS. Systems and Network Biology in Pharmaceutical Drug Discovery. 2014;20(1):2-3. PMID: 23530505.
10. Azmi AS, Sarkar FH. Prostate cancer stem cells: molecular characterization for targeted therapy. Asian J Androl. 2012 Sep;14(5):659-60. doi:10.1038/aja.2012.62. Epub 2012 Jun 25. PubMed PMID: 22728671; PubMed Central PMCID: PMC3734983.
11. Azmi AS. Network pharmacology for cancer drug discovery: are we there yet? Future Med Chem. 2012 May;4(8):939-41. doi: 10.4155/fmc.12.44. PMID: 22650234
12. Azmi AS, Mohammad RM, Sarkar FH. Can network pharmacology rescue neutraceutical cancer research? Drug Discov Today. 2012 Aug;17(15-16):807-9. doi:10.1016/j.drudis.2012.06.008. Epub 2012 Jun 16. PubMed PMID: 22727577.
13. Azmi AS. Reactivation of p53 pathways in cancer Curr. Phar. Design. 2011;17(6):534-5. PMID: 21391903.


Letters to the editor:

1. Azmi AS, Mohammad RM. Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in Bcell lymphomas: a possible role for activation-induced cytidine deaminase". Haematologica. 2013 Sep;98(9):e123. doi: 10.3324/haematol.2013.095299.


Book Authorships, Editorships, and Chapters
Book Editorships:

1. Editor of book entitled “Animal Models in Cancer Drug Discovery” Elsevier Academic Press ISBN 9780128147047 (2019)
2. Editor of book entitled “Conquering Ras in Cancer”. Elsevier Academic Press. ISBN 9780128035054 (2017)
3. Editor of Book entitled “Molecular Diagnostics and Therapy of Pancreatic Cancer: Systems Biology Approaches” from Elsevier Academic Press. ISBN 9780124081031 (2014)

Chapters (peer reviewed):
1. Khan HY*, Hadi SM, Mohammad RM and Azmi AS. Pro-oxidant Anti-cancer Activity of Plant derived Polyphenolic Compounds: An Under-appreciated Phenomenon. Functional Foods in Cancer Prevention and Therapy. Elsevier Academic Press 2020 ISBN 9780128161517 2020.
2. Al-Qambar B*, Chaker M*, Kamgar M*, Tesfaye A*, Wagner KU, Azmi AS. Protocols in genetic mice models of pancreatic cancer. Animal Models in Cancer Drug Discovery Elsevier Academic Press 2019 ISBN 9780128147047 Pages 107-123 (2019).
3. Azmi AS, Philip PA. Targeting Rho, Rac, CDC42 GTPase Effector p21 Activated Kinases in Mutant K-Ras-Driven Cancer “Conquering Ras in Cancer”. Elsevier Academic Press. ISBN 9780128035054 (2017)
4. Muqbil I, Azmi AS, Mohammad RM. Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy: A Resource Review. Elsevier Academic Press 2014 Azmi Ed. Pages ISBN 9780124081031. Pages 405-425 (2014).
5. Azmi AS, Mohammad RM. P53 re-activating small molecule inhibitors for the treatment of pancreatic cancer. Pancreatic Cancer - Molecular Mechanism and Targets, ISBN: 978-953-51-0410-0. (2012)
6. SM Hadi, MF Ullah, U Shamim, S Hanif, AS Azmi, SH Bhat. A prooxidant mechanism of red wine polyphenols in chemoprevention of cancer. Red Wine and Health 2009 edited by Paul O’Bryne, Nova Science Publishers (2009)
7. AS Azmi, SH Bhat, S Hanif, U Shamim, SM Hadi. A pro-oxidant mechanism of tea polyphenols in the prevention of cancer. Economic Crisis In Tea Industry edited by NK Jain, F Rahman, Peter Baker, Stadium Press, Texas, USA (2006)


Peer reviewed poster presentations (* trainee)
1. Evaluable antitumor activity in metastatic pancreatic adenocarcinoma with specific inhibitor of nuclear export based treatment. Asfar S. Azmi, Yosef Landesman, Michael Kauffman, Sharon Shacham, Gabriel Mpilla*, Amro Aboukameel*, Steve Kim, Mandana Kamgar*, Anteneh Tesfaye*,
Ramzi M. Mohammad, Philip A. Philip. AACR Annual Meeting 2019
2. Efficacy of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor, in preclinical models of gastrointestinal cancers Irfana Muqbil, Rachel Sexton*, Gabriel Mpilla*, Anteneh Tesfaye*, Steve Kim, Philip A. Philip, Amro Aboukameel*, Srikant Viswanadah, Kumar V. Penmesta, Ramzi M. Mohammad, Asfar S. Azmi. AACR Annual Meeting 2019
3. Nuclear exporter protein XPO1 a novel prognostic and therapeutic target in gastric cancer. Irfana Muqbil, Zaid Mahdi*, Rahman Choudhary*, Erkan Baloglu, William Senapedis, Yosef Landesman, Sharon Shacham, Michael Kauffman, Steve Kim, Rafic Beydoun, Richard N. Berri, Anthony Shields, Ramzi M. Mohammad, Asfar S. Azmi. AACR Annual Meeting Chicago April 14th-18th 2018
4. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Irfana Muqbil, Yiwei Li*, Erkan Baloglu, William Senapedis, Yosef Landesman, Christian Argueta, Michael Kauffman, Sharon Friedlander, Hua Chang, Sharon Shacham, Elisabeth Heath, Asfar S. Azmi. AACR Annual Meeting Chicago April 14th-18th 2018
5. PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors. Gabriel Mpilla*, Irfana Muqbil, Amro Aboukameel*, Philip A. Philip, William Senapedis, Erkan Baloglu, Yosef Landesman, Michael Kauffman, Sharon Shacham, Ramzi
M. Mohammad, Asfar S. Azmi. AACR Annual Meeting Chicago April 14th-18th 2018
6. Targeting cancer at the nuclear pore: some therapeutics into glioblastoma. Asfar S. Azmi. Neurogenomics and stem cell conference AMU Aligarh India, December 9-10 2017 (Invited Lecture).
7. Bruton Tyrosine Kinase Inhibition in Classical Hodgkin Lymphoma Cell Lines and Animal Models. Irfana Muqbil, Radhakrishnan Ramchandren, Ramzi M. Mohammad and Asfar S. Azmi. ASH Annual meeting December 12th 2017.
8. Clinical translation of nuclear export inhibitors in pancreatic cancer. Asfar S. Azmi, Philip A. Philip, Michael. Kauffman, Yosef. Landesman, William. Senapedis, Sharon. Shacham, Amit. Mahipal, Erkan. Baloglu, Irfana. Muqbil, Ramzi M. Mohammad. EACR-AACR-SIC June 24-27th 2017. Florence Italy. Proffered paper (oral presentation).
9. P21 activated kinase 4 as a novel therapeutic target for mTOR inhibitor Resistant Pancreatic Neuroendocrine Tumors Irfana Muqbil, Amro Aboukameel*, William Senapedis, Erkan Baloglu, Yosef Landesman, Michael Kauffman, Sharon Shacham, Philip A. Philip, Ramzi M. Mohammad and Asfar S. Azmi. EACR-AACR-SIC Special Conference 2017: The Challenges of Optimising Immuno and Targeted Therapies: From Cancer Biology to the Clinic, Florence, Italy 24 – 27 June 2017.
10. Novel role of xpo1 in regulating MicroRNAs related to pancreatic ductal adenocarcinoma invasion and metastasis. Asfar S. Azmi, Yiwei Li*, Irfana Muqbil, Amro Aboukameel*, William Senapedis, Erkan Baloglu, Yosef Landesman, Michael Kauffman, Sharon Shacham, Philip A. Philip, Ramzi M. Mohammad. AACR Annual Meeting, Washington DC, April 1-5 2017.
11. p21 activated kinase 4 (pak4) as a novel therapeutic target for non-hodgkin's lymphoma. Asfar S. Azmi, Yiwei Li, Irfana Muqbil, Amro Aboukameel*, William Senapedis, Erkan Baloglu, Yosef Landesman, Michael Kauffman, Sharon Shacham, Ayad Al-Katib, Ramzi M. Mohammad. AACR Annual Meeting, Washington DC, April 1-5 2017.
12. Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer. Asfar S. Azmi, Irfana Muqbil, Amro Aboukameel*, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Ramzi M. Mohammad, Philip A. Philip. AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care May 12-15, 2016.
13. The role of p21-activated kinase 4 (PAK4) in cancer stemness and epithelial-to-mesenchymal transition. Asfar S. Azmi, Irfana Muqbil, Amro Aboukameel*, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad. AACR Annual Meeting April 16-20, 2016 New Orleans, Louisiana, USA.
14. Nuclear protein targeted drugs: from bench to bedside. Asfar S. Azmi. Global Cancer Summit International conference. November 18th-20th 2015
15. Preclinical activity in non-Hodgkin’s lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies. Asfar S. Azmi, Amro Aboukameel*, Robert O. Carlson, Sivan Elloul, Sharon Shacham, Michael Kauffman, Ran Frenkel, Ramzi M. Mohammad. Abstract 1756 at the AACR Annual Meeting 2015
16. F-box protein fbxl5 nuclear retention by specific inhibitors of nuclear export induces snail ubiquitination leading to reversal of EMT. Irfana Muqbil, Amro Aboukameel*, Yosef Landesman, Michael Kauffman, Sharon Shacham, Ramzi M. Mohammad, Asfar S. Azmi. Abstract 1424 at the
AACR Annual Meeting 2015
17. Overcoming drug resistance and stemness in oncogenic kras driven pancreatic ductal adenocarcinoma through PAK4 inhibition. Asfar S. Azmi, William Senapedis, Erkan Baloglu, Yosef Landesman, Michael Kauffman, Sharon Shacham, Jack Wu, Amro Aboukameel*, Irfana Muqbil, Ramzi M. Mohammad. Abstract 4688 at the AACR Annual Meeting 2015.
18. Novel activity of selective inhibitors of nuclear export against Epithelial-to-Mesenchymal transition models. Asfar S. Azmi, Sharon Shacham, Michael Kauffman, Amro Aboukameel*, Ramzi M. Mohammad. Late Breaking Abstract. AACR Annual Meeting 2014.
19. Novel PAK4 Inhibitors for Pancreatic Cancer Therapy. Asfar S. Azmi, William T. Senapedis, Yossi Landesman, Erkan Bolaglu, Michael Kauffman, Sharon Shacham, Ramzi M. Mohammad. GI ASCO Meeting, San Francisco, Jan 16th to 18th 2014.
20. Selective Inhibitors of Mcl-1 with Potent Activity Against Multiple Myeloma Patient Cells and Animal Xenografts. Asfar S. Azmi, Zaneta Nikolovska-Coleska, Muneer Abidi, Kelley Marsack, Ashiq Masood*, Hiroshi Yano, Silvana Pregja, Jeffrey Zonder, Ramzi M. Mohammad. AACR Annual Meeting 2013, April 6th-10th Washington DC.
21. SNAIL inhibitor GN-25 induces MET through Global Reprograming of EMT Network Genes: a Systems and Network Analysis. Asfar S Azmi, Ramzi M Mohammad. AACR Chemical Systems Biology Meeting June 27th-30th Boston, MA USA.
22. Selective Targeting of Mcl-1 Induces Myeloma Cell Death and Synergizes with Proteasome Inhibitors. Asfar S. Azmi, Muneer Abidi, Nikolovska-Zaneta Coleska, Ramzi M. Mohammad and Jeffrey Zonder. 14th National Myeloma Workshop, April 4th 2013. Koyoto Japan.
23. Novel small molecule CRM-1 inhibitor for Non-Hodgkin’s Lymphoma. Asfar S. Azmi, Sharon Shacham, Dilara McCauley, Michael Kauffman, Ramzi M. Mohammad. 103rd Annual Meeting of the American Association for Cancer Research, Chicago, USA March 31st- April 4th 2011.
24. Design, synthesis and biological evaluation of two chemical classes as novel small molecule Mcl-1 inhibitors. Naval Bajwa, Fardokht Abulwerdi, Chenzhong Liao, Ahmed Mady, Julie Di Bernardo, Asfar S. Azmi, Tomek Cierpicki, Jeanne Stuckey, Hollis Showalter, Ramzi Mohammad, Zaneta Nikolovska-Coleska. 103rd Annual Meeting of the American Association for Cancer Research, Chicago, USA March 31st- April 4th 2011.
25. CRM-1 as a potential therapeutic target in pancreatic cancer. Asfar S. Azmi, Dilara McCauley, Sharon Shacham, Michael Kauffman, Ramzi M. Mohammad. 103rd Annual Meeting of the American Association for Cancer Research, Chicago, USA March 31st- April 4th 2011.
26. Novel small-molecule CRM-1 inhibitor for GI cancer therapy. Asfar S. Azmi, Michael Kauffman, Dilara McCauley, Sharon Shacham, Ramzi M Mohammad. 2012 GI ASCO Symposium San Diego January 2012.
27. Systems Biology and Network Modeling in Anti-Cancer Drug Discovery. Asfar S. Azmi, Ramzi M. Mohammad. Network Pharmacology symposium. Mol Med Tricon, San Francisco, Feb 2012..
28. Development of Novel CRM-1 inhibitor for Non-Hodgkin’s Lymphoma. Asfar S. Azmi, Ayad Al- Katib, Sharon Shacham, Michael Kauffman, Ramzi M. Mohammad. ASH Annual meeting San Diego, December 9th-13th 2011.
29. Snail-p53 interaction inhibitor GN25 and its combination with Oxaliplatin targets both hedgehog signaling and K-ras pathway in pancreatic cancer. Asfar S. Azmi, Bum-Joon Park and Ramzi M. Mohammad. 102nd Annual Meeting of the American Association for Cancer Research, Orlando Florida, USA April 2nd-6th 2011.
30. Zinc is Essential for the Efficacy of p53 Reactivating Drugs. Asfar S. Azmi, Ammar Sukari, Philip A. Philip and Ramzi M. Mohammad. 102nd Annual Meeting of the American Association for Cancer Research, Orlando Florida, USA April 2nd-6th 2011 DOI: 10.1158/1538-7445.AM2011-209.
31. Targeting Mcl-1 regulated apoptosis pathways as a novel therapy in pancreatic cancer. Fardokht Abulwerdi, Asfar S. Azmi, Meilan Liu, Amro Aboukameel, Chenzhong Liao, Jeanne Stuckey, Tomek Cierpicki, Ramzi M. Mohammad, Zaneta Nikolovska-Coleska. 102nd Annual Meeting of the American Association for Cancer Research, Orlando Florida, USA April 2nd-6th 2011.
32. Novel Mcl-1 inhibitors for Pancreatic Cancer Therapy. Naval Bajwa, Meilan Liu, Azmi, Asfar, Jeanne Stuckey, York Tomita, Ramzi M. Mohammad, Haian Fu, Zaneta Nikolovska-Coleska 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin Germany, Nov 16th-19th 2010.
33. Gossypol, a drug refined from cottonseed oil, sensitizes cancer cells to chemotherapy. Asfar S. Azmi, Omer Kucuk and Ramzi Mohammad. 3rd International Congress on Nutrition and Cancer, Bodrum, Turkey. October 20-24th 2010.
34. Plumbagin induces reactive oxygen species through a copper-redox cycle mechanism which mediates apoptosis in cancer cells: Implications for anticancer therapy Nazeem S, Asfar S. Azmi, Ramzi M. Mohammad, SM. Hadi and K. Satheesh Kumar. 3rd Annual Cancer Drug Symposium, Sudbury Ontario, Canada May 28-29th 2010.
35. Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: A putative mechanism for chemoprevention of cancer. SM Hadi, MF Ullah, AS Azmi, A Ahmad, U Shamim, H Zubair, HY Khan. Ist Conference of Resveratrol and Health, Elsinore, Denmark, September 13th-15th 2010.
36. A Putative Anticancer Mechanism of Plant Derived Polyphenols Mohd. Fahad Ullah, Uzma Shamim, Sarmad Hanif, Asfar S Azmi, Showket H Bhat and S.M.Hadi. 36th Annual Conference of Association of Clinical Biochemist of India (ACBICON) Pune, India, Nov 5th-7th 2009.
37. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for their anticancer properties. Asfar S. Azmi, Showket H. Bhat, Sarmad Hanif, Uzma Shamim, Mohammad Fahadullah and SM Hadi. International Symposium on Genomic Instability and Cancer. Jammu and Kashmir, India, July 22-26th 2007.


PRESENTATIONS
Podium Presentations (refereed)

1. Nuclear protein export as a novel therapeutic target in gastric cancer. Oral presentation (trainee Rachel Sexton). 13th International Gastric Cancer Congress. Abstract # IGCC-0030. May 8th-11 2019 Prague.
2. Nuclear Transport In Glioblastoma: novel therapeutic insights. World neurogenomics and stem cell therapy Conference 2017, India December 10th 2017
3. Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer. Proffered Abstract at the EACT-AACR-SIC, Florence Italy June 25th 2017
4. Nuclear Transport Inhibition of Cancer Therapy. SelectBio Drug Discovery Conference, Bangaluru India November 28th 2016
5. Targeting Cancer at the Nuclear Pore. Scientific Program Speaker, Global Cancer Summit organized by Global Health Cluster, Indian Institute of Sciences IISC Bangaluru, India, November 18-20th 2015.
6. Overcoming drug resistance and stemness in oncogenic kras driven pancreatic ductal adenocarcinoma through PAK4 inhibition. AACR Annual Meeting April 20th 2015
7. Nuclear protein transport inhibition for cancer therapy 2nd Protein-Protein Interaction GTC Bio Conference, October 23-24th 2014
8. Proffered abstract entitled pro-oxidant anticancer activity of resveratrol: an underappreciated phenomena 3rd Resveratrol Conference, Hawaii November 30th-December 3rd 2014
9. Systems biology in cancer drug discovery. Invited Speaker 3rd Online Drug Discovery Conference October 15th 2013.
10. Targeting cancer at the nuclear pore. Invited Speaker 3rd Target Meeting. November 12th 2013.
11. Network pharmacology in cancer drug discovery. CHI Healthtech Protein-Protein Interaction Drug Discovery Chemistry, San Diego April 17th 2013.
12. Speaker for CHI Healthtech MicroRNA in Cancer Symposium. Feb 15th 2012.
13. Second online Target Meeting Drug Discovery, October 17th 2012.
14. ASH Annual meeting award platform presentation San Diego, December 12th 2011
15. MDM2 inhibitor for pancreatic cancer therapy. First online International Target Meeting on Drug Discovery, October 20th 2011.

Faculty Status

Basic Science

← Return to listing